Cancer Moonshot

Cancer Moonshot. The Cancer Moonshot is a major federal initiative of the United States aimed at accelerating progress against cancer. Launched during the administration of Barack Obama and reignited under Joe Biden, its mission is to reduce the cancer death rate and improve the lives of patients and families. The initiative seeks to foster collaboration across government, the private sector, and non-profits to achieve a decade's worth of progress in half the time.

Background and launch

The initiative was first announced by President Barack Obama during his final State of the Union address in January 2016, tasking then-Vice President Joe Biden with its leadership following the death of his son, Beau Biden, from glioblastoma. The original effort was coordinated by the White House Office of Science and Technology Policy and the National Cancer Institute within the National Institutes of Health. In February 2022, President Joe Biden and First Lady Jill Biden officially reignited the mission, setting new ambitious goals for the coming decades. This renewal was influenced by advancements in science during the COVID-19 pandemic and built upon foundational work from the 21st Century Cures Act.

Goals and initiatives

The primary goal is to reduce the age-adjusted cancer death rate by at least 50% over the next 25 years. Key initiatives include improving early detection through new technologies like liquid biopsy, preventing more cancers through addressing environmental factors and promoting the HPV vaccine, and tackling inequities in care experienced by underserved communities. A major focus is on fostering data sharing through platforms like the Cancer Research Data Commons and supporting novel research in areas such as immunotherapy, mRNA vaccines, and precision oncology. The initiative also emphasizes improving the patient experience, including support for cancer survivors.

Progress and achievements

Notable progress includes the establishment of numerous public-private partnerships, such as the Biospecimen Pre-analytical Variables program with Frederick National Laboratory for Cancer Research. The Food and Drug Administration has approved several new therapies aligned with its aims, including T-cell engagers and bispecific antibodies. The launch of the ARPA-H (Advanced Research Projects Agency for Health) by the Biden administration was a direct outcome, modeled on DARPA to pursue high-risk biomedical breakthroughs. Furthermore, initiatives like the Childhood Cancer Data Initiative have expanded data infrastructure, and the Department of Veterans Affairs has implemented widespread lung cancer screening.

Funding and budget

Initial funding was authorized through the 21st Century Cures Act, which provided $1.8 billion over seven years to the National Institutes of Health. The reignited initiative has leveraged existing congressional appropriations and called for new funding, including a request for ARPA-H to receive $6.5 billion in mandatory funding. Additional resources have been directed through the Department of Health and Human Services, the Department of Defense, and the Department of Energy, the latter applying its supercomputing capabilities to oncology. Private sector commitments from organizations like the American Cancer Society and Stand Up To Cancer have also supplemented federal investment.

Criticism and challenges

Some critics, including researchers from Memorial Sloan Kettering Cancer Center and Johns Hopkins University, have argued that its aspirational goals may overlook the fundamental scientific complexity of metastasis and tumor heterogeneity. Concerns have been raised about potential duplication of efforts with existing programs at the National Cancer Institute and whether the focus on speed could compromise rigorous clinical trial design. Health equity advocates note persistent disparities in access to innovations across racial groups and geographic regions, such as Appalachia and the Mississippi Delta. The sustainability of funding beyond political cycles and the integration of the sprawling United States health care system remain significant structural hurdles.

Future directions

Future efforts are focused on implementing the National Cancer Plan, a strategic document released by the National Cancer Institute in 2023. Key directions include expanding the Cancer Screening Research Network to evaluate multi-cancer detection tests, driving the development of personalized cancer vaccines through partnerships with Moderna and BioNTech, and intensifying efforts in prevention and early detection. International collaboration, such as with the European Union's Europe's Beating Cancer Plan, will be emphasized. Long-term success is envisioned through sustained bipartisan support in Congress and deep engagement with the entire cancer community, from patients at MD Anderson Cancer Center to researchers at the Broad Institute. Category:Health initiatives in the United States Category:Oncology Category:Joe Biden